As we come to the end of another year, we’re kicking off our Year in Review with a look back at some of our top articles from 2024. The developments around Lykos Therapeutics’ MDMA-assisted therapy New Drug Application (NDA), which was submitted in late 2023 and ultimately rejected by FDA in August, dominated our coverage this year.
